AmMax Bio Reports Results of AMB-05X in P-II POC Study for the Treatment of Tenosynovial Giant Cell Tumor
Shots:
- The P-II POC study evaluates the safety, efficacy & PK of AMB-05X (IA) in 11 patients with TGCT of the knee for 12wk. of treatment
- In the P-II study, 8 out of 11 patients completed 12wk. of treatment with AMB-05X showed evidence of clinical benefit including tumor reduction based on RECIST criteria, improvements in patient-reported functional outcomes & QoL measures including reduction of pain & stiffness along with an increased range-of-motion of the affected joint
- The therapy showed efficacy across multiple clinical endpoints & enhanced safety profile compared to systemic therapies which are currently in development along with minimal-to-mild elevations were observed
Ref: Globe Newswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
